Bisphosphonate-functionalized cyclic Arg-Gly-Asp peptidomimetics

Carmelo Drago, a Daniela Arosio, b Cesare Casagrande, c and Leonardo Manzoni* b

a Università degli Studi di Milano, Centro Interdipartimentale Studi Biomolecolari e Applicazioni Industriali, Via Fantoli 16/15, Milano, I-20138, Italy
b Consiglio Nazionale delle Ricerche, Istituto di Scienze e Tecnologie Molecolari, Via Golgi 19, Milano, I-20133, Italy
c Università degli Studi di Milano, Dipartimento di Chimica, Via Golgi 19, I-20133 Milano, Italy

E-mail: Leonardo.manzoni@istm.cnr.it

Dedicated to Professor Richard R. Schmidt on the occasion of his 78th anniversary

DOI: http://dx.doi.org/10.3998/ark.5550190.0014.215

Abstract
We report the synthesis of three new conjugates between a cRGD integrin ligand and alendronic acid as a bisphosphonate anchor. The selected ligand is an RGD peptidomimetic, carrying the conformationally constrained RGD sequence on an azabicycloalkane scaffold and endowed with high affinity for integrin \( \alpha_v \beta_3 \). Since integrin \( \alpha_v \beta_3 \) is involved in the adhesion of osteoprogenitor cells and of osteoblasts, these constructs could prove useful as new tools for biofunctionalization of materials in biomedical application and for development of modern implants.

Keywords: Arg-Gly-Asp, integrins, bisphosphonate, peptidomimetics

Introduction

Osseointegration of implants is known to be a biological process that occurs by formation of a direct structural and functional connection between ordered living bone and the surface of a load carrying implant, without intervening soft tissue.\textsuperscript{1} Surface modifications have been shown to enhance osseointegration at early implantation times in terms of both velocity and intensity of bone formation. For example, rough surfaces can stimulate differentiation, growth and attachment of bone cells, and increases mineralization. The main methods reported in the literature to create implant roughness are acid etching, sandblasting, titanium plasma spraying and hydroxyapatite (HA) coating.\textsuperscript{2} Furthermore, the biofunctionalization of implant surfaces, by adding different substances to improve their biological characteristics, appear an important tool to enhance the capacity of osseointegration.\textsuperscript{3} A common theme in this field is the modification of
the material in order to promote selectively interactions with a specific cell type through biomolecular recognition events. Typically, peptides containing the cell-binding domains found in the extracellular matrix proteins are immobilized on the material to promote cell adhesion via ligand receptor interaction.\(^4\) Integrons are an example of cell adhesion receptors that bind to specific amino acid sequences, such as the RGD (Arg-Gly-Asp) sequence that is found in type I collagen, fibronectin, osteopontin and bone sialoprotein. Studies of collagen-coated surfaces\(^5\) have confirmed the improved ability of extracellular matrix-like surfaces to integrate implants into tissues, and the relevance of the RGD-motif in the adhesion of osteoprogenitor cells and of osteoblasts. The results have prompted research for the incorporation of RGD features into synthetic polymers suitable for implant coating\(^6\) and also for the direct linking of RGD-carrying sequence to the implant material,\(^7\) overcoming technological and biological problems of natural proteins. In particular, some papers explore the use of non-peptidic integrin ligands,\(^8\) or of cyclic peptide structure carrying phosphonate groups on titanium or bone surfaces.

Recently, we have designed and synthesized cyclic peptidomimetic ligands which contain the RGD recognition sequence embedded into novel azabicycloalkane scaffolds.\(^9\) These studies have produced some specific ligands with nanomolar affinity for \(\alpha_v\beta_3\) and \(\alpha_v\beta_5\) integrins, which are currently being profiled as anti-angiogenic agents.\(^10\) Among them, compound DB58 (Figure 1) contains a site suitable for conjugation to different functional units,\(^11\) which has been derivatized for application in medical diagnosis and therapy.\(^12\)

Our aim was the development of new coatings able to conjugate the \(\alpha_v\)-specific cyclic-RGD peptide to titanium implants or to hydroxyapatite-like objects or bone cements, using a methylene-bis-phosphonate moiety as anchor system. For practical reasons, such as commercial availability, biological characterization, and the presence in the same molecule of both the anchor and the conjugable functionalities, we chose alendronic acid (alendronate) as source of diphosphonic moiety. Sodium alendronate is a commonly used antiresorptive pharmacological agent that has been shown to be effective in osteopenic women for reducing bone resorption, increasing bone density, and decreasing fracture incidence.\(^13\) Furthermore, studies on the effect of alendronate on implant surface has been already reported in the literature.\(^14\) The capacity of phosphonic acid groups to bind strongly over a large pH range (pH 1-9) to TiO\(_2\),\(^15\) and the presence of two phosphonate groups can improve the binding of the coating molecule to the Ti surface.

In this experimental study the alendronate will be bridged with the cyclic-RGD peptide by spacers that differ for length, hydrophilicity or hydrophobicity, flexibility, as well as the type of conjugation.

Results and Discussion

The cyclic RGD peptidomimetic DB58 (Figure 1) which binds to \(\alpha_v\beta_3\) and \(\alpha_v\beta_5\) integrin receptors was developed by our group previously.\(^11\) The replacement of the D-Phe-Val dipeptide in the
lead structure cyclo(RGDfV)\textsuperscript{16} with an azabicycloalkane scaffold showing reverse-turn mimetic properties, constrains the RGD sequence into pre-organized conformations and provides the required affinity and selectivity for integrin antagonism. The functionalization of the scaffold with an heteroalkyl substituent enabled us to conjugate the RGD containing ligand with different diagnostic or therapeutic entities without losing activity.\textsuperscript{12}

As mentioned above, we selected alendronic acid \textbf{1} as the anchor and prepared three compounds differing for the distance between the anchor moiety and the targeting groups, for the type of conjugation and for the hydrophilicity of the linkers. In compound \textbf{6} the anchor group is directly conjugated to the RGD-carrying moiety, whereas in compounds \textbf{12} and \textbf{16} two linkers of different length are introduced. Compound \textbf{6} is accessible in a three step synthesis starting from 4-pentyoic acid \textbf{4}, activated as succinimidy ester followed by coupling with alendronic acid \textbf{1}. The regioselective copper-catalyzed Huisgen 1,3-dipolar cycloaddition between an azide and a terminal alkyne, often referred to as “click reaction”, has been reported to proceed in very good
yields in \( t \)-butanol/water, a solvent mixture that appeared ideal for dissolution of both linker and cyclopeptide. Thus, the “click” reactions of azide 2, with the terminal alkyne present in compound 5, \((\text{CuSO}_4, \text{Na L-ascorbate, } t\text{-BuOH, H}_2\text{O})\)\(^{17}\) proceeded without drawback reaching completion within 18 hours to give the corresponding triazole conjugates 6 in 80% yield after RP-HPLC purification. (Scheme 1)

![Scheme 1](image)

Scheme 1. i) NHS, DIC, DCM dry, r.t. 18 h, 1, H\(_2\)O, CH\(_3\)CN, NaOH until pH 7.2-7.4, 0 °C, 18 h, 70% over two steps; ii) Na-L-ascorbate, t-BuOH, H\(_2\)O, CuSO\(_4\), r.t., 18 h, 80%.

In the case of compound 12, an appropriate linker has been synthesized. The commercially available 4,7,10-trioxa-1,13-tridecanediamine 7 has been monoprotection at the nitrogen atom as the trityl derivative which was reacted with 4-pentynoic acid 4 using standard coupling procedures to give 8 in 55% yield over two steps. Compound 8 was treated with TFA in the presence of iPr\(_3\)SiH affording the deprotected compound. The resulting free amine was coupled with diglycolic anhydride to give the carboxylic acid 9 in 71% yield over two steps (Scheme 2).
Scheme 2. i) TrCl, Et$_3$N, DCM dry, r.t., 18 h; ii) 4, DIC, DCM dry, r.t., 18 h, 55% over two steps; iii) iPr$_3$SiH, TFA, r.t., 4 h; iv) diglycolic anhydride, pyridine, DMF, r.t., 4 h, 71% over two steps.

Scheme 3. (i) 9, Na L-ascorbate, t-BuOH, H$_2$O, CuSO$_4$, r.t., 18 h; (ii) NHS, DIC, DCM dry, r.t., 18 h, 1, CH$_3$CN, H$_2$O, NaOH until pH 7.2-7.4, 0 °C, 18 h, 55% over two steps; (iii) TFA, thioanisole, iPrSiH, ethanediol, phenol, water, r.t., 18h, 84%.
With compound 9 in hand, the next task was to couple the linker and the integrin ligand to create the desired triazolyl-linked conjugates. An attempt to perform the click reaction between compound 9 and the unprotected integrin ligand 2 afforded the desired product in poor yield. Better results were obtained using the protected integrin ligand. Thus, completely protected azide 10 has been “clicked” with linker 9 to give the corresponding triazolyl conjugate. Activation of the carboxylic acid with N-hydroxysuccinimide (NHS) and N,N′-diisopropylcarbodiimide (DIC) followed by the addition of alendronate 1 gave the desired conjugate protected compound 11 in 55% over three steps. Finally, the side chain protecting group has been removed by TFA in presence of scavengers (thioanisole, phenol, iPr₃SiH) to give the desired compound 12 in 84% yield (Scheme 3).

**Scheme 4.** (i) 14, HOBt, EDC, DIPEA, DCM dry, r.t. 2h; (ii) H₂, Pd/C, MeOH, r.t., 2h; (iii) diglycolic anhydride, DMF, pyridine, r.t., 4h, 52% over three steps; (iv) NHS, DIC, DCM dry, r.t., 18h, 1, CH₃CN, H₂O, NaOH until pH 7.2-7.4, 0°C, 18 h, 84% over two steps; (v) TFA, thioanisole, iPrSiH, ethandiol, phenol, water, r.t., 18h, 93%.
In the case of the last compound, the known linker $14^{12d}$ was linked with the amino derivative integrin ligand $13^{11b}$ using $N$-(3-Dimethylaminopropyl)-$N'$-ethylcarbodiimide hydrochloride (EDC), 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine (DIPEA) as coupling agents, followed by hydrogenation on Pd/C under standard condition to remove the benzyloxy carbonyl protecting group on the nitrogen. The resulting free amine was reacted with diglycolic anhydride to obtain the carboxylic acid $15$ in 52% yield over three steps, ready for following reactions. Coupling of the intermediate $15$ and alendronic acid $1$ using standard reagents, followed by side chain protecting groups removal by TFA in presence of scavengers, gave the final product $16$ in 78% yield over three steps and after RP-HPLC purification (Scheme 4).

**Receptor binding assay**

The derivatives $6$, $12$, and $16$ were examined *in vitro* for their abilities to inhibit the binding of biotinylated vitronectin to the isolated, immobilized $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrin receptors (Table 1). Affinities of commercially available compound c(RGDfV) and our starting compound DB58 were determined as references, in the same assays. The functionalized cyclic pentapeptides $6$, $12$, and $16$ displayed a binding affinity toward $\alpha_v\beta_3$ integrin in the nanomolar range, comparable or slightly lower than unconjugated DB58.

Although some differences in the binding affinities, probably due to the different nature and length of the linkers, all the three synthesized compounds still interact well with integrin $\alpha_v\beta_3$, thus confirming that the functionalization of the scaffold does not influence the binding activity.

**Table 1. Inhibition of biotinylated vitronectin binding to $\alpha_v\beta_3$ and $\alpha_v\beta_5$ receptors*$$^a$$**

| Entry | Compound | IC$_{50}$ (nM) ± SD for $\alpha_v\beta_3$ | IC$_{50}$ (nM) ± SD for $\alpha_v\beta_5$ |
|-------|----------|----------------------------------------|----------------------------------------|
| 1     | c(RGDfV) | 3.0 ± 1.6                              | 17.4 ± 3.3                             |
| 2     | DB58     | 22.6 ± 3.5                             | 205 ± 33.5                             |
| 3     | 6        | 50.3 ± 13.4                            | 475 ± 44                               |
| 4     | 12       | 242.6 ± 62.9                           | 1979 ± 835                             |
| 5     | 16       | 20.5 ± 15.3                            | 721 ± 99                               |

* IC$_{50}$ values were calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism 5 program. All values are the mean (± standard deviation) of triplicate determinations.

**Conclusions**

In conclusion: we have synthesized three new conjugates between an integrin ligand and a methylene-bis-phosphonate anchor, choosing alendronic acid, to improve binding to the surface
of appropriate materials, such as titanium or hydroxyapatite. On the basis of the results obtained in the solid phase receptor binding assay, the conjugation of a biologically relevant entity on the appendage of the azabicycloalkane scaffold does not affect the affinity of the RGD ligand toward the integrin receptors.
Thus, these new conjugates could be used for biofunctionalization of materials in biomedical applications, and could find application in the development of modern implants. Biological evaluation in vitro and in vivo of these new compounds will be reported in due course.

**Experimental Section**

**General.** All chemicals and solvents were of reagent grade and were used without further purification. Solvents were dried by standard procedures and reactions requiring anhydrous conditions were performed under nitrogen or argon atmosphere. $^1$H and $^{13}$C NMR spectra were recorded at 300 K on a Bruker Avance-600 or Bruker Avance-400 spectrometer. Chemical shifts $\delta$ for $^1$H and $^{13}$C are expressed in ppm relative to internal Me$_4$Si as standard. $^{31}$P NMR spectra were recorded on a 400 MHz spectrometer operating at 162 MHz, with complete proton decoupling. $^{31}$P NMR spectroscopic chemical shifts are reported in ppm (δ) relative to external 85% H$_3$PO$_4$ at 0 ppm. Signals were abbreviated as s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were obtained with Agilent 1100 analytical HPLC equipped with diode array detector and Bruker ion-trap Esquire 3000+ with ESI. Thin layer chromatography (TLC) was carried out with pre-coated Merck F$_{254}$ silica gel plates. Elemental analyses were performed by the staff of the microanalytical laboratory of our department. Flash chromatography was carried out with Macherey-Nagel silica gel 60 (230-400 mesh) or using SP1 (single-column) Biotage flash purification system (with C18 cartridges). Preparative HPLC was performed using MS-based preparative HPLC system Waters. Semi-preparative HPLC was carried out on a Waters SymmetryPrep C$_{18}$-7$\mu$m 7.8 × 300 mm column or a Waters Atlantis C$_{18}$ OBD 5$\mu$m 19 mm × 10 cm.

**Synthesis of compound 5.** 4-Pentynoic acid (98.1 mg, 1.0 mmol) was dissolved in dry CH$_2$Cl$_2$ (10 ml), and then N-hydroxysuccinimide (NHS) (115.09 mg, 1.0 mmol) and N,N'-diisopropylcarbodiimide (DIC) (387 μl, 2.5 mmol) were sequentially added. The reaction mixture was stirred at room temperature overnight. After reaction completion, the solvent was removed under reduced pressure. The crude was left under high vacuum. The crude product was diluted in CH$_3$CN (20 ml) and the corresponding solution was slowly added to a solution of alendronic acid trihydrate (975 mg, 3 mmol) (solubilized with water (8 ml) and the pH of the corresponding solution was adjusted to pH 7.2-7.4 adding a 0.1 M water solution of NaOH, finally to the mixture was added CH$_3$CN (24 mL)) at 0 °C using a syringe pump (40 μl/min). The reaction mixtures was left under stirring 18 h at 0 °C. After reaction completion, the crude product was precipitated by addition of ethanol to obtain 5 as a dirty white solid (277 mg, 0.84
mmol, 70%). 1H NMR (400 MHz, D2O): δ: 1.85-1.75 (m, 2H), 1.95-1.85 (m, 2H), 2.34 (t, J 2.0 Hz, 1H), 2.41 (m, 4H), 3.18 (t, J 6.8 Hz, 2H); 13C NMR (100 MHz, CDCl3): 174.6, 83.6, 70.3, 40.2, 34.6, 31.2, 23.4, 14.6. Anal. Calcd for C9H17NO8P2 (329.04): C, 32.84; H, 5.21; N, 4.26%. Found: C, 32.88; H, 5.30; N, 4.26%.

**Synthesis of compound 6.** A 0.9 M water solution of sodium ascorbate (45 µl, 0.4 mmol) and a 0.3 M water solution of CuSO4 (65 µl, 0.02 mmol) were sequentially added to stirred solution of compound 5 (32.9 mg, 0.10 mmol) and DIC (310 µl, 2.0 mmol) in a 1:1 mixture of H2O/t-BuOH (300 µl). The reaction mixture was stirred overnight at room temperature and then the solvent was removed under reduced pressure. Finally, the residue was purified by chromatography on a C18 reversed phase semi-preparative hplc column and then lyophilized. HPLC eluant conditions: from 98% of H2O (0.1% TFA) and 2% of CH3CN (0.1% TFA) to 70% of H2O (0.1% TFA) and 30% of CH3CN (0.1% TFA), flow rate 12 ml/min., 30 min. runs, giving pure 6 (71.4 mg, 0.08 mmol, 80%).

1H NMR (400 MHz, D2O + 5% TFA): δ: 1.12 (m, 1H, H-5), 1.32-1.57 (m, 4H, 2 H7-Arg, Hβ-Arg, H-7), 1.63 (m, 2H, NHCH2CH2CH2(COH)(PO3H2), 1.68-1.98 (m, 4H, H-8, CH2CH2-C(OH)(PO3H2), Hβ-Arg), 2.22-2.40 (m, 3H, H-5, H-7, H-8), 2.45-2.60 (m, 3H, COCH2CH2-triazole, Hβ-Asp), 2.91 (m, 1H, Hβ-Asp), 2.93-3.10 (m, 6H, COCH2CH2-triazole, 2 H8-Arg, NHCH2CH2CH2(COH)(PO3H2), 3.25 (m, 1H, H-4), 3.36 (d, J 16 Hz, 1H, Hα-Gly), 3.91 (m, 1H, H-6), 4.10 (d, J 16 Hz, 1H, Hα-Gly), 4.15 (m, 1H, H-9), 4.18-4.36 (m, 3H, 2 H-10, Hα-Asp), 4.38-4.47 (m, 2H, H-3, Hα-Arg), 8.10 (s, 1H, H triazole); 13C NMR (100 MHz, D2O): δ: 174.7, 174.0, 173.0, 171.7, 169.3, 156.8, 62.2, 55.8, 52.9, 51.6, 51.3, 42.4, 40.4, 39.7, 36.2, 35.2, 32.7, 32.2, 30.1, 27.0, 24.4, 21.1; 31P-NMR (161.9 MHz, D2O): δ: 21.4. Anal. Calcd for C31H30N12O15P2 (892.30): C, 41.71; H, 5.65; N, 18.83%. Found: C, 41.75; H, 5.64; N, 18.84%; MS (ESI+) m/z: 893.5 (M+H+), 447.3 (M+2H+).

**Synthesis of compound 8.** Compound 7 (11.02 g, 50.0 mmol) was dissolved in dry CH2Cl2 (50 ml), and then TEA (209 µl, 1.5 mmol) and TrCl (278.8 mg, 1.0 mmol) were sequentially added. The reaction mixture was stirred at room temperature 18 h. After reaction completion, the mixtures was washed with a saturated solution of NaHCO3 (3 x 20 ml). The organic layer was dried over Na2SO4, and then the solvent removed under reduced pressure. The crude product was purified by flash chromatography (Biotage™ eluant conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2). Yield 85% (393 mg, 0.85 mmol) of pure compound. Anal. Calcd for C29H38N2O3 (462.29): C, 75.29; H, 8.28; N, 6.06%. Found: C, 75.28; H, 8.30; N, 6.05%.

The compound (462.6 mg, 1.0 mmol) was dissolved in dry CH2Cl2 and then pentyloic acid (147.2 mg, 1.5 mmol) and DIC (310 µl, 2.0 mmol) were sequentially added. The reaction mixture was stirred at room temperature overnight. After reaction completion, the solvent was removed under reduced pressure and the crude product was purified by flash chromatography (Biotage™ eluant conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2). Yield 65% (353 mg, 0.65 mmol) of pure 8.
$^1$H NMR (400 MHz, CDCl$_3$): δ: 1.71 (m, 4H, -CH$_2$CH$_2$CH$_2$-), 1.88 (s, 1H, C=CH), 2.12 (bs, 2H, Ph$_2$NHCH$_2$-), 2.27 (t, J 7.2 Hz, 2H, -CH$_2$C=CH), 2.44 (m, 2H, -CH$_2$CO-), 3.31 (dd, J 12.0, 5.6 Hz, 2H, -CH$_2$NHCO-), 3.6-3.35 (m, 12H, -CH$_2$-), 6.30 (bs, 1H, -NHCO), 7.10 (t, J 7.2 Hz, 3H, Ph), 7.20-7.15 (m, 6H, Ph), 7.39 (d, J 7.6 Hz, 6H, Ph); $^{13}$C NMR (100 MHz, CDCl$_3$): δ: 170.8, 146.3, 128.7, 126.2, 83.1, 70.6, 70.3, 70.1, 70.0, 69.1, 41.0, 38.2, 38.0, 35.5, 35.3, 30.6, 28.7, 14.9. Anal. Calcd for C$_{34}$H$_{42}$N$_2$O$_4$: C, 54.80; H, 7.74; N, 6.73%. Found: C, 54.85; H, 7.75; N, 6.72%. MS (ESI$^+$) m/z: 543.4 (M+H$^+$).

**Synthesis of compound 9.** Compound 8 (543 mg, 1.0 mmol) was treated with iPr$_3$SiH (410 μl, 2.0 mmol) and TFA (153 μl, 2.0 ml). The reaction mixture was stirred at room temperature for 2-4 hours. After reaction completion, TFA was removed under reduced pressure and the crude product was diluted with water and the mixtures was extracted with iPr$_2$O (3 X 20 ml). Water was removed under reduced pressure and the crude product was used on the following step without any further purification.

The crude product was dissolved in DMF and then diglycolic anydride (232 mg, 2.0 mmol) and pyridine (323 μl, 4.0 mmol) were sequentially added. The reaction mixture was stirred at room temperature for 4 hours. After reaction completion, water was added to the reaction mixture. Finally, the solvent was removed under reduced pressure and the crude product was purified by flash chromatography on Biotage using a C$_{18}$ reverse column (Biotage$^\text{TM}$ eluant conditions: 1% of CH$_3$CN and 99% of H$_2$O to 100% of CH$_3$CN and 0% of H$_2$O). Yield 71% (295 mg, 0.71 mmol) of pure 9.

$^1$H NMR (400 MHz, CDCl$_3$): δ: 1.82 (m, 4H, -CH$_2$CH$_2$CH$_2$-), 2.02 (m, 1H, C=CH), 2.46 (m, 2H, -CH$_2$C=CH), 2.54 (m, 2H, -CH$_2$CO), 3.41 (m, 4H, -CH$_2$NH), 3.67-3.55 (m, 12H, -CH$_2$-), 4.11 (d, J 3.6 Hz, 2H, -CO-CH$_2$O-), 4.19 (d, J 4 Hz, 2H, -CO-CH$_2$O-), 6.77 (bs, 1H, -NH), 7.64 (bs, 1H, -NH); $^{13}$C NMR (100 MHz, CDCl$_3$): δ: 172.0, 171.8, 1697, 82.9, 71.7, 70.4, 70.3, 70.2, 70.0, 69.9, 69.5, 69.4, 69.3, 42.6, 38.2, 36.9, 35.3, 29.0, 28.7, 14.9. Anal. Calcd for C$_{10}$H$_{12}$N$_2$O$_8$ (416.22): C, 54.80; H, 7.74; N, 6.73%. Found: C, 54.85; H, 7.75; N, 6.72%. MS (ESI$^+$) m/z: 417.3 (M+H$^+$).

**Synthesis of compound 11.** A 0.9 M water solution of sodium ascorbate (45 μl, 0.4 mmol) and a 0.3 M water solution of CuSO$_4$ (65 μl, 0.02 mmol) were sequentially added to stirred solution of compound 10 (83.2 mg, 0.10 mmol) and of the alkyne 9 (41.6 mg, 0.10 mmol) in a 1:1 mixture of H$_2$O/iPr$_2$OH (300 μl). The reaction mixture was stirred 18 h at room temperature and then the solvent was removed under reduced pressure. Finally, the residue was purified by Biotage$^\text{TM}$ flash chromatography on a C$_{18}$ reverse column (Biotage$^\text{TM}$ eluant conditions: 1% of CH$_3$CN and 99% of H$_2$O to 100% of CH$_3$CN and 0% of H$_2$O). Yield 65% (81.2 mg, 0.65 mmol).

Anal. Calcd for C$_{35}$H$_{38}$N$_3$O$_{18}$S (1247.59): C, 52.91; H, 6.86; N, 14.59%. Found: C, 52.95; H, 6.87; N, 14.61%. MS (ESI$^+$) m/z: 1249.1 (M+H$^+$), 625.4 (M+2H$^+$).

The above compound (81.2 mg, 0.065 mmol) was dissolved in dry CH$_2$Cl$_2$ (1 ml), and then NHS (7.5 mg, 0.065 mmol) and DIC (25.2 μl, 0.1625 mmol) were sequentially added. The reaction mixture was stirred at room temperature overnight. After reaction completion, the solvent removed under reduced pressure. The crude was left under the high vacuum. The crude product
was diluted in CH$_3$CN (2 ml) and the corresponding solution was slowly added to a solution of alendronate (63.4 mg, 0.195 mmol), was solubilized with 4 mL of water and the pH of the corresponding solution was adjusted to pH 7.2-7.4 adding a 0.1 M water solution of NaOH, finally to the mixture were added 12 mL of CH$_3$CN at 0 °C using a syringe pump (40 μl/min). The reaction mixtures was left under stirring over night at 0 °C. After reaction completion, the solvent was removed under reduced pressure and the crude product was purified by HPLC using a C$_{18}$ reverse column (HPLC eluant conditions: from 90% of H$_2$O (0.2% TFA) to 10% of CH$_3$CN (0.2% TFA) to 0% of H$_2$O (0.2% TFA) and 100% of CH$_3$CN (0.2% TFA), flow rate 12 ml/min, 30 min. runs). Yield 84% (80.8 mg, 0.0546 mmol) of pure protected compound. 

$^1$H NMR (400 MHz, D$_2$O): δ: 1.24 (m, 1H, H-5), 1.32-1.48 (m, 12H, 2 H$_7$-Arg, Hβ-Arg, COC(CH$_3$)$_3$), 1.58 (m, 1H, H-7), 1.64 (m, 2H, OCH$_2$CH$_2$CH$_2$NH), 1.71-1.87 (m, 6H, OCH$_2$CH$_2$CH$_2$NH, NHCH$_2$CH$_2$CH$_2$C(OH)(PO$_3$H$_2$)$_2$, H-8, Hβ-Arg), 1.97 (m, 2H, NHCH$_2$CH$_2$CH$_2$C(OH)(PO$_3$H$_2$)$_2$), 2.06 (s, 3H, CH$_3$ Mtr), 2.25-2.38 (m, 3H, H-5, H-7, H-8), 2.50 (s, 3H, CH$_3$ Mtr), 2.53-2.64 (m, 6H, CH$_3$ Mtr, COCH$_2$CH$_2$-triazole, Hβ-Asp), 2.92 (dd, J 7.6 Hz, J 16.4 Hz, 1H, Hβ-Asp), 2.98 (m, 2H, COCH$_2$CH$_2$-triazole), 3.07-3.19 (m, 4H, 2 Hδ-Arg, OCH$_2$CH$_2$CH$_2$NH), 3.19-3.23 (m, 5H, H-4, NHCH$_2$CH$_2$CH$_2$C(OH)(PO$_3$H$_2$)$_2$, OCH$_2$CH$_2$CH$_2$NH), 3.43 (t, J 6.2 Hz, 2H, OCH$_2$CH$_2$NH), 3.48 (m, 1H, Ha-Gly), 3.51 (t, J 6.2 Hz, 2H, OCH$_2$CH$_2$NH), 3.54-3.66 (m, 8H, OCH$_2$), 3.81 (s, 3H, OCH$_3$ Mtr), 3.95 (m, 1H, H-6), 4.05 (s, 2H, OCH$_2$CO), 4.06 (s, 2H, OCH$_2$CO), 4.12-4.17 (m, 3H, H-9, H-10, Ha-Gly), 4.32-4.43 (m, 4H, H-10, Ha-Asp, H-3, Ha-Arg), 6.75 (s, 1H, H Mtr), 7.85 (s, 1H, H triazole); $^{13}$C NMR (100 MHz, D$_2$O): δ: 174.7, 173.7, 172.0, 171.6, 169.2, 112.8, 83.1, 70.0, 69.6, 69.4, 68.6, 68.4, 62.2, 55.8, 52.9, 52.1, 51.3, 42.5, 39.4, 36.4, 36.3, 36.2, 34.9, 34.7, 32.7, 32.3, 30.8, 29.7, 28.3, 27.3, 23.3, 23.1, 20.7, 11.4. Anal. Calcd for C$_9$H$_{98}$N$_{14}$O$_{24}$P$_2$S (1478.59): C, 47.90; H, 6.54; N, 13.25%. Found: C, 47.87; H, 6.55; N, 13.28%; MS (ESI$^+$) m/z: 1480.0 (M+H$^+$), 741.0 (M+2H$^+$).

**Synthesis of compound 12.** A mixture composed of TFA (5 ml), 5% of thianisole (250 μL) 5% triisopropylsilane (250 μL), 5% ethandiol, 5% Phenol (275 mg) and 5% water (250 μL) was added to a stirred solution of compound 11 (80.8 mg, 0.0546 mmol). The reaction mixtures were left stirring at room temperature overnight and then concentrated under reduced pressure. The crude product was solubilized with water (10 ml) and washed with EtOAc (3 X 10 ml), Et$_2$O (3 X 10 ml), iPr$_2$O (3 × 10 ml), hexane (3 × 10 ml), DCM (3 × 10 ml), CHCl$_3$ (3 × 10 ml), iPr$_2$O (3 × 10 ml). Finally, water was removed under reduced pressure. When the crude was not sufficiently pure, the residue was purified by chromatography on a C$_{18}$ reversed phase semi-preparative hplc column and then lyophilized. HPLC eluant conditions: from 98% of H$_2$O (0.1% TFA) and 2% of CH$_3$CN (0.1% TFA) to 70% of H$_2$O (0.1% TFA) and 30% of CH$_3$CN (0.1% TFA), flow rate 12 ml/min., 30 min. runs. Yield 84% (55.5 mg, 0.0459 mmol) of pure 12.

$^1$H NMR (400 MHz, D$_2$O): δ: 1.26 (m, 1H, H-5), 1.42-1.60 (m, 4H, 2 H$_7$-Arg, Hβ-Arg, H-7), 1.64 (m, 2H, OCH$_2$CH$_2$CH$_2$NH), 1.70-1.88 (m, 5H, OCH$_2$CH$_2$CH$_2$NH, NHCH$_2$CH$_2$CH$_2$C(OH)(PO$_3$H$_2$)$_2$, H-8), 1.90-2.08 (m, 3H, NHCH$_2$CH$_2$CH$_2$C(OH)(PO$_3$H$_2$)$_2$, Hβ-Arg), 2.27-2.47 (m, 3H, H-5, H-7, H-8), 2.54 (m, 2H, COCH$_2$CH$_2$-triazole), 2.66 (dd, J 17.2 Hz, J 6.8 Hz, 1H, Hβ-Asp), 2.95 (m, 2H, COCH$_2$CH$_2$-triazole), 3.02, (dd, J 17.2 Hz, J 7.6 Hz, 1H, Hβ-Asp), 3.07-
3.18 (m, 4H, 2 Hδ-Arg, OCH₂CH₂CH₂NH), 3.18-3.30 (m, 5H, H-4, NHCH₂CH₂-CH₂C(OH)(PO₃H₂), OCH₂CH₂CH₂NH), 3.40 (t, J 6.2 Hz, 2H, OCH₂CH₂CH₂NH), 3.47 (m, 1H, Ha-Gly), 3.51 (t, J 6.2 Hz, 2H, OCH₂CH₂CH₂NH), 3.54-3.66 (m, 8H, OCH₂), 4.00 (m, 1H, H-6), 4.05 (s, 2H, OCH₂CO), 4.06 (s, 2H, OCH₂CO), 4.14-4.28 (m, 3H, H-9, H-10, Ha-Gly), 4.33-4.47 (m, 3H, H-10, Ha-Asp, H-3), 4.54 (m, 1H, Ha-Arg), 7.81 (s, 1H, H triazole); ¹³C NMR (100 MHz, D₂O): δ: 174.7, 174.6, 174.5, 173.9, 173.0, 171.6, 169.2, 156.8, 124.5, 70.0, 69.6, 69.4, 68.5, 68.3, 62.2, 55.8, 52.9, 51.8, 51.7, 51.3, 42.4, 40.4, 39.4, 36.4, 36.3, 36.2, 34.9, 33.3, 32.7, 32.3, 30.9, 30.1, 28.3, 27.0, 24.4, 23.3, 20.8; ³¹P-NMR (161.9 MHz, D₂O): δ: 20.4. Anal. Caled for C₁₅H₂₆N₄O₂; P₂ (1210.48): C, 44.63; H, 6.33; N, 16.19%. Found: C, 44.68; H, 6.34; N, 16.24%; MS (ESI⁺) m/z 1211.7 (M+H⁺), 606.7 (M+2H⁺).

**Synthesis of 15.** Compound 13 (34.1 mg, 0.11 mmol) was dissolved in dry CH₂Cl₂ (1 ml), and then EDC (23 mg, 0.12 mmol), HOBT (16.2 mg, 0.12 mmol) and DIPEA (70 μl, 0.4 mmol) were sequentially added. The reaction mixture was stirred at room temperature for 15 min. before adding the compound 12 (100.7 mg, 0.125 mmol). The reaction mixture was stirred at room temperature overnight, and then the solvent was removed under reduced pressure, and the residue was purified by Biotage™ flash chromatography on a C₁₈ reverse column (Biotage™ eluant conditions: 1% of CH₃CN and 99% of H₂O to 100% of CH₃CN and 0% of H₂O). Yield 74% (83.6 mg, 0.074 mmol).

¹H NMR (400 MHz, CDCl₃): δ: 8.13 (bs, 1H), 7.69 (bs, 1H), 7.27-7.15 (m, 5H), 7.00 (bs, 1H), 6.45 (s, 1H), 6.32 (m, 1H), 5.57 (m, 1H), 5.02 (m, 2H), 4.57 (m, 1H), 4.38 (m, 2H), 4.19 (m, 2H), 4.13 (m, 2H), 3.75 (s, 3H), 3.57 (m, 6H), 3.44 (m, 2H), 3.41 (m, 1H), 3.31 (m, 2H), 3.26 (m, 1H), 3.12 (m, 2H), 2.90 (m, 1H), 2.60 (m, 3H), 2.52 (s, 3H), 2.48 (m, 1H), 2.32 (m, 3H), 2.04 (s, 9H), 1.87 (m, 3H), 1.70-1.45 (m, 4H), 1.35 (s, 9H), 1.15 (m 1H); ¹³C NMR (100 MHz, CDCl₃): δ: 173.2, 171.4, 170.6, 169.8, 136.6, 128.5, 128.1, 111.8, 83.1, 70.9, 70.5, 70.3, 70.0, 66.7, 62.5, 55.7, 55.5, 40.8, 36.2, 34.9, 33.5, 30.4, 28.3, 28.0, 24.1, 18.3, 12.0. Anal. Caled for C₅₂H₇₆N₁₀O₁₆S (1128.52): C, 55.31; H, 6.78; N, 12.40%. Found: C, 55.40; H, 6.77; N, 12.41%. Catalytic amount of 10% Pd-C was added to solutions of the above compounds (56.5 mg, 0.05 mmol) in MeOH (3 ml). The resulting mixture was stirred at room temperature for ca. 2 hours under hydrogen (1 atm). After reaction completion, the mixture was filtered through a Celite pad, and then washed with MeOH (3 × 1 ml). The combined organic solution was concentrated under reduced pressure. The crude product was dissolved in DMF dry (1 ml) and then diglycolic anhydride (23.2 mg, 0.2 mmol) and pyridine (32 μl, 0.4 mmol) were sequentially added. The reaction mixture was stirred at room temperature for 4 hours. After reaction completion, water was added to the reaction mixture. Finally, the solvent was removed under reduced pressure and the crude product was purified by flash chromatography on Biotage using a C₁₈ reverse column (Biotage™ eluant conditions: 1% of CH₃CN and 99% of H₂O to 100% of CH₃CN and 0% of H₂O). Yield 70% (38.9 mg, 0.035 mmol) of pure 15.

¹H NMR (400 MHz, CDCl₃): δ: 1.27 (m, 1H, H-5), 1.43 (s, 9H, COC(CH₃)₃), 1.43-1.68 (m, 4H, 2 Hγ-Arg, Hβ-Arg, H-7), 1.79-1.97 (m, 2H, H-8, Hβ-Arg), 2.05 (s, 3H, CH₃ Mtr), 2.20-2.40 (m, 3H, H-5, H-7, H-8), 2.40-2.58 (m, 4H, CH₂ Mtr, Hβ-Asp), 2.60 (s, 3H, CH₃ Mtr), 2.75 (m, 1H,
H-4), 2.92 (dd, J 6.6 Hz, J 16.6 Hz, 1H, Hβ-Asp), 3.00-3.12 (m, 2H, H-10, Hδ-Arg), 3.18 (m, 1H, Hδ-Arg) 3.27 (m, 1H, H-10), 3.33-3.48 (m, 3H, OCH₂CH₂NH, Ha-Gly), 3.52 (t, J 4.8 Hz, 2H, OCH₂CH₂NH), 3.54-3.69 (m, 8H, OCH₂), 3.75 (s, 3H, OCH₃ Mtr), 3.92 (s, 2H, OCH₂CO), 3.98-4.09 (m, 3H, H-6, OCH₂CO), 4.04 (s, 2H, OCH₂CO), 4.11-4.24 (m, 2H, H-9, Ha-Gly), 4.39 (m, 1H, H-3), 4.49 (m, 1H, Ha-Asp), 4.55 (m, 1H, HA-Arg), 6.10-6.41 (m, 3H, NH guanidinium), 6.45 (s, 1H, H Mtr), 7.15 (m, 1H, NHCH₂azabicycloalkane), 7.30 (m, 1H, NHazabicycloalkane), 7.41 (m, 1H, NH-Arg), 7.60 (m, 1H, NH linker), 7.74 (m, 1H, NH-Gly), 8.29 (m, 1H, NH-Asp); ¹³C NMR (100 MHz, CDCl₃): δ: 173.2, 171.5, 170.6, 169.8, 136.6, 111.8, 83.1, 71.2, 70.9, 70.4, 70.3, 70.2, 70.0, 69.6, 69.0, 62.4, 55.7, 55.5, 38.8, 36.0, 34.9, 33.5, 30.4, 28.3, 24.1, 18.3, 12.0. Anal. Calcd for C₄₈H₇₄N₁₀O₁₅S (1110.49): C, 51.88; H, 6.71; N, 12.60%. Found: C, 51.87; H, 6.72; N, 12.61%. MS (ESI⁺) m/z 1111.9 (M+H⁺).

**Synthesis of 16.** Compound 15 (111.1 mg, 0.1 mmol) was dissolved in dry CH₂Cl₂ (1 ml), and then NHS (11.5 mg, 0.1 mmol) and DIC (39 μl, 0.25 mmol) were sequentially added. The reaction mixture was stirred at room temperature 18 h. After reaction completion, the solvent was left under reduced pressure. The crude was left under the high vacuum overnight. The crude product was diluted in CH₂CN (2 ml) and the corresponding solution was slowly added to a solution of alendronate 1 (97 mg, 0.3 mmol, was solubilized with water (4 ml) and the pH of the corresponding solution was adjusted to pH 7.2-7.4 adding a 0.1 M water solution of NaOH, finally to the mixture was added CH₂CN (12 mL)) at 0 °C using a syringe pump (40 μl/min). The reaction mixtures was left under stirring over night at 0 °C. After reaction completion, the solvent was removed under reduced pressure and the crude product was purified by HPLC using a C₁₈ reverse column. HPLC eluant conditions: from 90% of H₂O (0.2% TFA) and 10% of CH₂CN (0.2% TFA) to 0% of H₂O (0.2% TFA) and 100% of CH₂CN (0.2% TFA), flow rate 12 ml/min., 30 min. runs. Yield 84 % (124 mg, 0.084 mmol) of pure protected compound.

¹H NMR (400 MHz, CDCl₃): δ: 7.65 (bs, 1H), 6.72 (s, 1H), 4.46 (t, J 7.2 Hz, 1H), 4.33 (m, 2H), 4.18 (m, 2H), 4.04 (d, J 4.4 Hz, 4H), 3.96 (s, 2H), 3.93 (m, 1H), 3.78 (s, 3H), 3.64 (d, J 6.0 Hz, 8H), 3.59 (t, J 5.2 Hz, 2H), 3.41 (m, 3H), 3.20 (t, J 6.8 Hz, 3H), 3.08 (m, 3H), 2.90 (m, 1H), 2.74 (m, 1H), 2.56 (s, 3H), 2.47 (s, 3H), 2.47-2.25 (m, 3H), 2.02 (s, 3H), 1.95 (m, 2H), 1.90-1.55 (m, 5H), 1.38 (s, 9H), 1.22 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ: 174.8, 174.5, 173.7, 172.8, 172.0, 171.8, 171.6, 171.5, 170.1, 112.7, 83.1, 70.4, 70.0, 69.7, 69.6, 69.4, 68.8, 62.1, 55.9, 55.7, 52.9, 51.5, 42.5, 40.0, 39.3, 38.6, 35.7, 34.8, 33.3, 32.9, 32.5, 30.9, 30.2, 29.7, 27.3, 26.8, 23.3, 23.1, 17.6, 11.4.

A mixture composed of TFA (5 ml), 5% of thioanisole (250 μl) 5% trisopropylsilane (250 μl), 5% ethandiol, 5% Phenol (275 mg) and 5% water (250 μL) was added to a stirred solution of protected compound (0.084 mmol). The reaction mixtures were left stirring at room temperature overnight and then concentrated under reduced pressure. The crude product was solubilized with water (2 ml) and washed with EtOAc (3 × 2 ml), Et₂O (3 × 2 ml), iPr₂O (3 × 2 ml), hexane (3 × 2 ml), DCM (3 × 2 ml), CHCl₃ (3 × 2 ml), iPr₂O (3 × 2 ml). Finally, water was removed under reduced pressure. When the crude was not sufficiently pure, the residue was purified by chromatography on a C₁₈ reversed phase semi-preparative hplc column and then lyophilized.
HPLC eluant conditions: from 98% of H$_2$O (0.1% TFA) and 2% of CH$_3$CN (0.1% TFA) to 70% of H$_2$O (0.1% TFA) and 30% of CH$_3$CN (0.1% TFA), flow rate 12 ml/min., 30 min. runs. Yield 93% (83.8 mg, 0.078 mmol) of pure 16.

$^1$H NMR (400 MHz, D$_2$O): δ: 1.26 (m, 1H, H-5), 1.42-1.70 (m, 4H, H$\gamma$-Arg, H$\beta$-Arg, H-7), 1.73-1.89 (m, 3H, NHCH$_2$CH$_2$CH$_2$(OH)(PO$_3$H$_2$)$_2$, H-8), 1.90-2.10 (m, 3H, NHCH$_2$CH$_2$CH$_2$(OH)(PO$_3$H$_2$)$_2$, H$\beta$-Arg), 2.34-2.51 (m, 3H, H-5, H-7, H-8), 2.69 (dd, J 17.0 Hz, J 7.0 Hz, 1H, H$\beta$-Asp), 2.78 (m, 1H, H-4), 3.00-3.30 (m, 7H, H$\beta$-Arg, 2H$\delta$-Arg, 2H-10, NHCH$_2$CH$_2$CH$_2$(OH)(PO$_3$H$_2$)$_2$), 3.37-3.53 (m, 3H, OCH$_2$C$_2$H$_2$NH, H$\alpha$-Gly), 3.60 (m, 3H, OCH$_2$CH$_2$NH), 3.63-3.74 (m, 8H, OCH$_2$), 3.92-4.04 (m, 3H, OCH$_2$CO, H-6), 4.07 (s, 4H, OCH$_2$CO), 4.20-4.32 (m, 2H, H-9, H$\alpha$-Gly), 4.36 (d, J 8.4 Hz, 1H, H-3), 4.48 (t, J 7.0 Hz, 1H, H$\alpha$-Asp), 4.55 (m, 1H, H$\alpha$-Arg); $^{13}$C NMR (100 MHz, D$_2$O): δ: 174.8, 174.5, 174.0, 173.0, 172.8, 171.9, 171.6, 170.2, 156.4, 70.3, 70.0, 69.7, 69.6, 69.4, 68.8, 62.2, 56.0, 53.0, 51.7, 51.5, 42.5, 40.4, 40.0, 39.4, 38.6, 35.7, 33.3, 32.9, 32.5, 30.8, 30.2, 26.9, 24.5, 23.3; $^{31}$P-NMR (161.9 MHz, D$_2$O): δ: 20.7. Anal. CaIcd for C$_{38}$H$_{65}$N$_{11}$O$_{21}$P$_2$ (1073.38): C, 42.50; H, 6.10; N, 14.35%. Found: C, 42.60; H, 6.11; N, 14.38%. MS (ESI$^+$) m/z: 1074.6 (M+H$^+$).

Biology

Solid-phase receptor binding assay

Purified α$_v$β$_3$ and α$_v$β$_5$ receptors (Chemicon International, Inc., Temecula, CA, USA) were diluted to 0.5 µg/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl$_2$, 2 mM CaCl$_2$, and 1 mM MgCl$_2$. An aliquot of diluted receptors (100 µL/well) was added to 96-well microtiter plates (NUNC MW 96F Medisorp Straight) and incubated overnight at 4°C. The plates were then incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for an additional 2 h at room temperature to block nonspecific binding, followed by 3 h incubation at room temperature with various concentrations (10$^{-5}$–10$^{-12}$ M) of test compounds in the presence of biotinylated vitronectin (1 µg/mL). Biotination was performed using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing, the plates were incubated for 1 h at room temperature with biotinylated streptavidin–peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min incubation with 100 µL/well Substrate Reagent Solution (R&D Systems, Minneapolis, MN) before stopping the reaction with the addition of 50 µL/well 2N H$_2$SO$_4$. Absorbance at 415 nm was read in a SynergyTM HT Multi-Detection Microplate Reader (BioTek Instruments, Inc.). Each data point represents the average of triplicate wells; data analysis was carried out by nonlinear regression analysis with GraphPad Prism software. Each experiment was repeated in triplicate.

Acknowledgements

The authors thank CNR and MUR (FIRB RBNE03LF7X and PRIN 2006030449 research projects) for financial support.
References

1. (a) Albrektsson, T. *J. Prosthet. Dent.* **1983**, *50*, 255. (b) Bränemark, P. I. *J. Prosthet. Dent.* **1983**, *50*, 399.

2. (a) Wong, M.; Eulenberger, J.; Schenk, R.; Hunziker, E. *J. Biomed. Mater Res A* **1995**, *29*, 1567. (b) Wennerberg, A.; Albrektsson, T. *Int. J. Oral Maxillofac. Implants* **2010**, *25*, 63.

3. Novaes, A. B. Jr.; de Souza, S. L.; de Barros, R. R.; Pereira, K. K.; Iezzi, G.; Piattelli, A.; *Braz. Dent. J.* **2010**, *21*, 471.

4. (a) Rezania, A.; Healy, K. E. *Biotechnol. Prog.* **1999**, *15*, 19. (b) Rezania, A.; Thomas, C. H.; Branger, A. B.; Waters, C. M.; Healy, K. E. *J. Biomed. Mater. Res.*** **1997**, *37*, 9.

5. Masi, L.; Franchi, M.; Santucci, M.; Danielli, D.; Arganini, L.; Giannone, V.; Formigli, L.; Benvenuti, S.; Tanini, A.; Beghé, F.; Mian, M.; Brandi, M. L. *Calciﬁ. Tissue Int.* **1992**, *51*, 202.

6. Hersel, U.; Dahmen, C.; Kessler, H. *Biomaterials* **2003**, *24*, 4385.

7. El-Ghannam, A. R.; Ducheyne, P.; Risbud, M.; Adams, C. S.; Shapiro, I. M.; Castner, D.; Golledge, S.; Composto, R. J. *J. Biomed. Mater Res A* **2004**, *68*, 615.

8. (a) Auernheimer, J.; Zukowski, D.; Dahmen, C.; Kantlehner, M.; Enderle, A.; Goodman, S. L.; Kessler, H. Chembiochem 2005, 6, 2034. (b) Dahmen, C.; Auernheimer, J.; Meyer, A.; Enderle, A.; Goodman, S. L.; Kessler, H. *Angew. Chem. Int. Ed.* **2004**, *43*, 6649.

9. Belvisi, L.; Bernardi, A.; Checchia, A.; Manzoni, L.; Potenza, D.; Scolastico, C.; Castorina, M.; Cupelli, A.; Giannini, G.; Carminati, P.; Pisano, C. *Org. Lett.* **2001**, *1001*.

10. (a) Belvisi, L.; Riccioni, T.; Marcellini, M.; Chiarucci, I.; Efrati, D.; Vesci, L.; Potenza, D.; Scolastico, C.; Manzoni, L.; Lombardo, K.; Stasi, M. A.; Nico, B.; Ribatti, D.; Presta, M.; Carminati, P.; Pisano, C. *Molecular Cancer Therapeutics* **2005**, *4*, 1670. (b) Belvisi, L.; Bernardi, A.; Colombo, M.; Manzoni, L.; Potenza, D.; Scolastico, C.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; LoGiudice, P.; Pisano, C. *Bioorg. Med. Chem.* **2006**, *14*, 169.

11. (a) Manzoni, L.; Arosio, D.; Belvisi, L.; Bracci, A.; Colombo, M.; Invernizzi, D.; Scolastico, C. *J. Org. Chem.*, **2005**, 4124. (b) Manzoni, L.; Belvisi, L.; Arosio, D.; Civera, M.; Pilkinson-Miksa, M.; Potenza, D.; Caprini, A.; Araldi, E. M. V.; Monferini, E.; Mancino, M.; Podestà, F.; Scolastico, C. *ChemMedChem*, **2009**, *4*, 615.

12. (a) Arosio, D.; Manzoni, L.; Araldi, E. M. V.; Caprini, A.; Monferini, E.; Scolastico, C. *Bioconj. Chemistry*, **2009**, 1611. (b) Arosio, D.; Manzoni, L.; Araldi, E. M. V.; Scolastico, C. *Bioconj. Chemistry*, **2011**, *22*, 664. (c) Lanzardo, S.; Conti, L.; Brioschi, C.; Bartolomeo, M. P.; Arosio, D.; Belvisi, L.; Manzoni, L.; Maiocchi, A.; Maisano, F.; Forni, G. *Contrast Media Mol. Imaging*, **2011**, *6*, 449. (d) Manzoni, L.; Belvisi, L.; Arosio, D.; Bartolomeo, M. P.; Bianchi, A.; Brioschi, C.; Buonsanti, F.; Cabella, C.; Casagrande, C.; Civera, M.; De Matteo, M.; Fugazza, L.; Lattuada, L.; Maisano, F.; Miragoli, L.; Neira, C.; Pilkinson-Miksa, M.; Scolastico, C. *ChemMedChem*, **2012**, *7*, 1084.
13. (a) Bone, H. G.; Downs, R. W. Jr.; Tucci, J. R.; Harris, S. T.; Weinstein, R. S.; Licata, A. A.; McClung, M. R.; Kimmel, D. B.; Gertz, B. J.; Hale, E.; Polvino, W. J. *J. Clin. Endocrinol. Metab.* **1997**, *82*, 265. (b) Chapurlat, B. D.; Delmas, P. D. *Osteoporos. Int.* **2009**, *20*, 1299.

14. Frenkel, S. R.; Jaffe, W. L.; Della Valle, C.; Jazrawi, L.; Maurer, S.; Baitner, A.; Wright, K.; Sala, D.; Hawkins, M.; Di Cesare, P. E. *J. Biomed. Mater. Res. A* **2001**, *58*, 645.

15. Péchy, P.; Rotzinger, F. P.; Nazeeruddin, M. K.; Kohle, O.; Zakeeruddin, S. M.; Humphry-Baker, R.; Grätzel, M. J. *Chem. Soc. Chem. Commun.* **1995**, *65*.

16. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. *J. Am. Chem. Soc.* **1996**, *118*, 7461.

17. Arosio, D.; Bertoli, M.; Manzoni, L.; Scolastico, C. *Tetrahedron Lett.*, **2006**, *47*, 3697.